ZymoGenetics, Inc. (NASDAQ:ZGEN) and Bristol-Myers Squibb Company (NYSE:BMY) announced that interim results from Phase 2a of the EMERGE clinical trial of PEG-Interferon lambda administered with ribavirin in treatment-naïve hepatitis C virus patients, will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting in Boston, October 29 – November 2, 2010. PEG-Interferon lambda abstracts, including clinical, pharmacokinetic and viral kinetic data along with in vitro data in combination with direct-acting antiviral agents, were published today and are available on the AASLD website at www.aasld.org.

AASLD 2010 PEG-Interferon lambda Poster Presentations
 

Title: Pegylated Interferon Lambda (PEG-IFN-λ) Phase 2 Dose-Ranging, Active-Controlled Study in Combination with Ribavirin (RBV) for Treatment-Naïve HCV Patients (Genotypes 1, 2, 3, or 4): Safety, Viral Response, and Impact of IL-28B Host Genotype through Week 12

Abstract: 821

Presenter: A.J. Muir

Date: Sunday, October 31, 2010

Time: 8:00 AM – 5:30 PM
 

Title: Pharmacokinetics of PEG-Interferon lambda (PEG-IFN-λ) Following Fixed Dosing in Treatment-Naïve Hepatitis C Subjects (Single Dose Interim Data from a Dose-Ranging Phase 2A Study)

Abstract: 830

Presenter: K.A. Byrnes-Blake

Date: Sunday, October 31, 2010

Time: 8:00 AM – 5:30 PM
 

Title: The Effect of Treatment Group, HCV Genotype, and IL28B Genotype on Early HCV Viral Kinetics in a Phase 2A Study of PEG-Interferon lambda (PEG-IFN-λ) in Hepatitis C Patients

Abstract: 831

Presenter: J.A. Freeman

Date: Sunday, October 31, 2010

Time: 8:00 AM – 5:30 PM
 

Title: In vitro activity of the combination of pegylated interferon lambda (PEG-IFN-λ) with direct-acting antivirals in the HCV replicon model

Abstract: 1854

Presenter: F. McPhee

Date: Tuesday, November 2, 2010

Time: 7:00 AM - 12:00 PM

About PEG-Interferon lambda

PEG-Interferon lambda (IL-29) is a novel and first in class interferon in development for hepatitis C. The native human interferon lambda proteins are generated by the immune system in response to viral infection, and signal through a different receptor than type I interferons, such as interferon alpha. Because this receptor is present on fewer cell types within the human body, it is hypothesized that PEG-Interferon lambda may be able to demonstrate an improved safety and tolerability profile compared to alpha interferons.